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This special issue of Virulence is concerned with new trends 
and developments in biodefense research with emphasis in bac-
terial pathogens and toxins. Although the wealth of research 
approaches targeting this elite class of pathogens is increasing, 
there is an apparent gap in translating the accumulated infor-
mation into effective medical countermeasures compliant with 
the current regulatory environment. This issue contains com-
prehensive reviews and covers a variety of innovative strategies 
for biosurveillance, molecular diagnostics, novel discovery, 
molecular tools, and alternative therapeutic interventions with 
focus on light-based platforms and immunotherapeutics. Special 
attention is placed on cornerstone biodefense pathogens such 
as Bacillus anthracis, Burkolderia pseudomallei, and Francisella 
tularensis.
Introduction
The possibility of biological warfare and bioterrorism has 
become an increasing concern to both military planners and civil 
defense authorities worldwide. Letters containing anthrax spores 
sent to destinations within the US in 2001 brought the sudden 
realization that bioterrorism is not merely a theoretical threat but 
a real and present danger. Although emergency preparedness and 
response capabilities exist throughout the Western hemisphere, 
the focus and availability of resources to deal with the actual and 
urgent health issues due to biological warfare has been diverted.1 
This new threat awareness motivated the research community 
to create at least two peer review journals in biodefense and also 
led to an extensive debate regarding how bioterrorism responses 
compare with those for pandemics and natural disasters.2 The 
rigorous debate led to the mobilization of the scientific commu-
nity, comprehensive research efforts, coordination of resources, 
and a first generation of medical countermeasures.3
A list of microorganisms/biological agents that pose the high-
est risk to national security and public health are classified as 
Category A select agents based on a set of considerations defined 
by the US Centers for Disease Control and generally approved 
by similar agencies worldwide. These biological agents share 
common alarming characteristics, as they are (1) highly morbid 
and lethal; (2) highly infectious or highly toxic; (3) amenable 
in wide distribution in an active form; (4) easily produced in 
bulk and easily stored until delivered; (5) reasonably hardy in the 
environment after distribution; and (6) amenable to genetic engi-
neering to be resistant to antibiotics. The major challenge that is 
posed by these agents includes, among others, the treatment of 
infected/contaminated individuals. Antibiotic-resistant microor-
ganisms are potentially near-ideal biological weapons.
Key Bacterial Biological Warfare Agents (BWAs)
These considerations can be met by a relatively small group 
of agents that can be divided into five classes of which repre-
sentative examples include the bacterial species Bacillus anthracis, 
Fransicella tularensis, Yersinia pestis, Brucella melitensis/abortus, 
and Burkholderia pseudomallei/mallei. They are causative agents 
of fatal diseases such as anthrax, plague botulism, brucellosis 
tularemia, melioidosis, and glanders. There is a pressing need 
to elucidate their virulence and pathogenicity traits and trans-
late the impact on the host by developing novel diagnostic and 
therapeutic tools and countermeasures. The chronological, geo-
graphical and epidemiological fingerprint of melioidosis exempli-
fies the need for comprehensive biodefense research efforts and 
their expected impact.4 Melioidosis caused by B. pseudomallei is 
an equipotent biological threat with public health importance 
in endemic areas, particularly Thailand and northern Australia, 
with increasing frequency in other parts of the world. US ser-
vicemen have been exposed to the causative agent during the 
Vietnam War era where it was noted that helicopter crews seemed 
to have a high incidence of the disease. This and its long incuba-
tion period resulted in melioidosis acquiring the sobriquet “the 
Vietnamese time bomb”, although remote exposures resulting in 
sporadic cases have continued to surface in the US.5 Endemic 
melioidosis in Southeast Asia is on the rise, and in combination 
with the recent threat of gram-negative multidrug and pandrug 
antibiotic resistance, it was upgraded from a local time bomb in a 
global significant health concern.
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Over the last few years, the availability of genome sequences, 
metagenomic analyses, proteomic tools, and databases has 
increased geometrically for key biodefense bacterial pathogens.6-11 
The same applies for molecular microbiology and genetic manipu-
lation techniques, such as the development of random insertional 
mutants for B. pseudomallei,12 the allelic exchange in F. tularen-
sis,13 and the genome-wide screens for B. anthracis.14 Finally, the 
reproducibility and regulatory compliance for relevant animal 
models is debatable, as it is reflected from comparative studies in 
F. tularensis and Burkholderia sp.15 It is evident that the research 
activities centered around biodefense bacterial pathogens are 
active and vibrant, but there is a clear scientific gap, as well as a 
variety of unmet challenges for the development of effective diag-
nostic and therapeutic approaches and countermeasures.
Genomic-Wide Biosurveillance Approaches  
for Tracking Pathogen Virulence
The first paper by Willy Valdivia-Granda16 correlates advances 
in genomic research with the unmet need to closely monitor and 
validate microbial biodefense threats. The lack of such systems 
compromises significantly any attempts to prioritize counter-
measure needs and consequently hinders their development. The 
essential elements of a reliable biosurveillance system that sup-
ports a diverse community of users are described. A number of 
main obstacles and challenges for the development of this sys-
tem are outlined. Despite the impressive advances in data mining 
capabilities, the real-time content analysis suffers from critical 
inconsistencies due to oversimplification attributed, for example, 
in the inability of social media to depict the factual reality. The 
inherent quality of the provided information is discussed and 
special notions are made for the counter effect of biased refer-
encing and hash tags. This first article, more than any that fol-
lows in this issue, combines presentation of genomic scientific 
information with the social perspective and federal institutional 
responses to biological warfare agents (BWAs)
Broad Spectrum Biosensors for Diagnosis  
in Biodefense
A variety of different physicochemical instrumental tech-
niques have been used for direct and indirect identification of 
bacteria as the basis for biosensor construction. The list includes: 
infrared and fluorescence spectroscopy, flow cytometry, chroma-
tography, chemiluminescence techniques, as well as alternative 
enzyme- and immune-based assays. The idea of designing broad 
spectrum biosensors capable of identifying diverse organisms is 
quite appealing and the process is gradually transitioning from 
the bench top into the clinic. Metzgar et al.17 discuss novel bio-
sensor technologies for the identification of a variety of pathogens 
based on bioinformatic signature-matching processes. A clear 
distinction is made between technological approaches to detect 
individual organisms with those sensing microbial communities. 
Emphasis is placed on the impact of the latter approaches in bio-
defense applications, as well as the amenability for sensing uncul-
turable or extremely hazardous microorganisms.
Comparative Analysis of PCR-Based Assays  
for the Detection of B. anthracis Chromosomal 
Fingerprints
The specific identification of B. anthracis and its differentia-
tion from the closely related Bacillus cereus and Bacillus thuringien-
sis species remains a major diagnostic problem. The commercially 
available diagnostic kits targeting plasmid-markers have proved 
unable to distinguish B. anthracis from the non-anthracis Bacillus 
species. These kits usually harbor anthrax-specific virulence plas-
mids (pXO1 and pXO2) and B. anthracis strains that don’t carry 
plasmids. Ågren et al.18 provide a comprehensive analysis for both 
types of PCR-based assays for the detection of B. anthracis. They 
coupled experimental with in silico comparative methodologies 
for all the signature sequences available for the causative agent 
of anthrax. They comment on the sensitivity and the specific-
ity of their observations: Out of the 35 PCR assays investigated, 
only 4 were 100% specific for the B. anthracis chromosome. 
Further testing of 6 assays, including the WHO recommended 
procedures, employing a collection of 90 Bacillus strains resulted 
in 3 adequately performing assays that share the same chromo-
somal marker location: the lambdaBa03 prophage region (PL3, 
BA5345, and BA5357).
The Staphylococcal Enterotoxins Pathogenicity, 
Host Responses, and Intervention Strategies
Krakauer and Stiles19 provide a comprehensive review of a 
key virulence and pathogenicity determinant family of tox-
ins—the staphylococcal enterotoxins (SEs). Although an aero-
solized staphylococcal enterotoxin B (SEB) toxin weapon would 
not likely produce significant mortality, it could render 80% or 
more of exposed personnel ill and unable to function for weeks. 
Therefore, SEB has been historically considered as a potential 
BWA. These protein toxins target mainly the major histocompat-
ibility complex class II on antigen-presenting cells and specific 
Vβ regions of T-cell receptors, resulting in potentially life-threat-
ening stimulation of the immune system. The article summarizes 
models and molecular tools developed over the years to study the 
interaction of SEB with the host, as well as highlights progress 
on current therapeutic interventions with emphasis on vaccines.
Ribosome-Inactivating Proteins as Molecular Tools
Ribosome-inactivating proteins (RIPs) are protein synthe-
sis inhibitors that act at the ribosome. They have been shown 
to exhibit RNA N-glycosidase activity and depurinate the 28S 
rRNA of the eukaryotic 60S ribosomal subunit. Members of the 
family include shiga and shiga-like toxins type I (trichosanthin 
and luffin) and type II (ricin, agglutinin, and abrin) RIPs. They 
have been considered as valuable molecular tools conjugated to 
monoclonal antibodies (immunotoxins to target cancer) or in the 
case of trichosanthin, targeting T cells and macrophages after 
an HIV-1 infection. Walsh et al.20 report recent mechanistic 
findings regarding fungal ribotoxins and reviews the newly dis-
covered Burkholderia lethal factor 1 (BLF1). BLF1 and fungal 742 Virulence  Volume 4 issue 8
ribotoxins don’t possess RNA N-glycosidase activity despite their 
ability to block protein synthesis. This new evidence is the basis 
of a discussion for the classification and the exact functional and 
enzymatic capabilities of RIPs.
Small RNA-Mediated Regulation  
of Host–Pathogen Interactions
Small RNAs (sRNAs) constitute a large and heterogeneous 
regulator class implicated in bacterial gene expression. Bacterial 
sRNAs share functional similarity to eukaryotic microRNAs as 
global posttranscriptional regulators, through targeting mul-
tiple mRNAs by base pairing with multiple downstream target 
mRNAs to prevent translation.21 Transcriptome sequencing 
reveals evidence for the presence of hundreds of different sRNAs 
in some bacterial species. The multiple regulatory roles in micro-
bial physiology prioritizes them as a compelling class of targets 
in drug discovery. Harris et al.22 emphasizes recent trends and 
molecular mechanistic facts and discoveries for the role of bacte-
rial, viral, and human sRNAs in regulation of pathogen virulence 
and host immunity. The application of these findings in thera-
peutic approaches for biodefense bacterial pathogens is exten-
sively discussed.
A Light-Based Therapeutic Platform for BWAs
Vatansever et al.23 presents the challenges for opportunities 
employing light to develop a series of therapeutic applications for 
BWAs. Two major distinctions are made as far as it concerns UV 
and visible light: the germicidal effect of UV (UVC), a case is 
made for broad and selective microbicidal effect for bacteria and 
viruses and the photocatalytic, but also the potential effect in vac-
cine development for UVA. Visible light can destroy microorgan-
isms alone—blue light is considering highly microbicidal with 
the ability to eradicate also bacterial spores. Finally, a special seg-
ment is devoted to photodynamic therapy (PDT). The concept of 
photodynamic inactivation in PDT requires microbial exposure 
to visible light energy that causes the excitation of exogenous pho-
tosensitizer molecules resulting in the production of singlet oxy-
gen and other reactive oxygen species that react with intracellular 
components, and consequently produce cell inactivation. Besides 
the antimicrobial potential and range of PDT, the selectivity as 
well as the stimulation of the host immune system is discussed.
Adherence and Uptake of Francisella  
into Host Cells
Pulmonary exposure to F. tularensis results in the majority 
of the cases in severe lung pathology and a high mortality rate. 
During the early infection steps, the lack of induction of classical 
inflammatory mediators, including IL1-β and TNF-α has been 
observed. This led to the suggestion that F. tularensis probably is 
capable of evading detection by host innate immune surveillance 
and/or actively suppresses inflammation. The Francisella viru-
lence factors and pathogenicity determinants, especially those 
that facilitate the interaction with the host, are largely uncharac-
terized and poorly understood. Very little is known regarding the 
invasion path and the host signaling cascades following invasion. 
Moretto and Mann24 provide insights and updates regarding key 
adhesion and virulence factor genes in Francisella that are homol-
ogous to those involved in type IV pilus structure and assembly, 
including 6 genes encoding putative major pilin subunit proteins, 
present in the genome of the highly virulent Schu S4 strain. As 
attachment and internalization are essential in the pathogenic-
ity process, this article offers insights for pathways that can be 
exploited in drug discovery.
Biofilms: An Advancement in Our Understanding  
of Francisella Species
Biofilm formation is a central virulence and antimicrobial 
resistance ingredient, as well as the molecular determinants and 
pathways related with biofilm production, in key nosocomial 
pathogens. The multiple roles of these microbial communities 
have been studied extensively with emphasis in the role of the 
capsule, carbohydrate quorum sensing, and two-component sig-
naling systems. The ability of Francisella spp. to form biofilms 
as part of its pathogenesis arsenal is a recent and relatively unex-
plored area. Nevertheless, van Hoek25 collected and evaluated an 
unparalleled data set from recent studies and make the case for 
the contribution of Francisella biofilms in environmental toler-
ance and survival. van Hoek interrogates major Francisella cell 
structural and functional elements, identifies their relation with 
the biofilm phenotype, and translates this information into viru-
lence determination and clinical significance.
Particle Size and Pathogenicity  
in the Respiratory Tract
The respiratory track is a common niche and target for many 
select agent BWAs, especially for the 3 key pathogens that are 
extensively discussed in this issue. This is pivotal in the com-
prehensive understanding of pathogenicity, infectivity and 
host responses to aerosolized parthogens. Thomas26 focuses on 
respiratory track infectivity and makes the interesting correla-
tion between animal models currently under investigation and 
humans. Apart from the direct comparison and simulation, a 
significant portion of his analysis is centered around particle 
size, comparative infectivity between upper and lower respira-
tory track, and clinical manifestation attributed to either type 
of infection.
Immunotherapy for Tularemia
One appealing platform under investigation in a variety of 
pathological conditions is adjuvant immunotherapeutics. The 
selective stimulation of protective immune responses can serve 
as an alternative treatment option for bacterial infections. In 
order to elicit appropriate immune responses and to avoid unde-
sirable inflammatory tissue damage, it is essential to identify www.landesbioscience.com Virulence 743
ligands and receptor pathways that specifically control protective 
responses at the infection site. The key biodefense pathogens are 
not exempt, but on the contrary they are intensively interrogated 
for the development of immunotherapeutic interventions. This 
approach has been recently explored. Skyberg27 examines the 
utility of the platform in tularemia. He reviews the advances in 
the field for identifying compelling therapeutic targets in F. tula-
rensis and discusses the challenges in translational research and 
target deployment against tularemia.
Conclusions and Future Perspectives
Research in BWAs and biodefense applications has been 
attracting attention, populating the literature and energizing 
military and civilian authorities and planners for the last decade. 
This excessive mobility is the result of an increase in the fre-
quency of viable bioterrorism threats and the risk of intentional 
dissemination of BWAs. On the other hand, the biosafety secu-
rity requirements for biodefense research as well as the nature of 
BWAs generates, by default, additional technical challenges in 
expediting successful countermeasures. These challenges share 
similarities and differences with the ones attributed to emerging 
multidrug resistant pathogens. The increasing antibiotic resis-
tance over the past 50 years has transformed many dogmas in 
antimicrobial drug discovery leading to a gloomy prognosis of 
untreatable infections. The great era of antibiotic discovery and 
relative predictions for the “end of infectious diseases” are fol-
lowed by the current consensus belief for the “end of the anti-
biotic era”.28 The response to biothreats appears more stochastic 
and comprehensive. The articles in this special issue highlight 
recently developed innovations and thematic biodefense pri-
orities interventions to combat BWAs. They highlight sensitive 
diagnostic identification approaches and attractive therapeutic 
platforms under investigation that may prove helpful in develop-
ing new treatments or improve existing ones. Special thanks to all 
the authors for their excellent contributions and the publishing 
team of Virulence (Sara Sharpe and Eva Riedmann) for their help 
during the past 9 months in compiling this issue. We hope that 
readers will find in this issue new avenues of research in the fight 
against BWAs.
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